Showing results (71-80 of 379) with videos related to
Sort By:
Pageof 38
Journal of the American College of Cardiology|September 3, 2011
Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysisSunil V Badve, Matthew A Roberts, Carmel M Hawley, et al.Journal of the American Society of Nephrology : JASN|May 1, 2010
Long-term cancer risk of immunosuppressive regimens after kidney transplantationMartin P Gallagher, Patrick J Kelly, Meg Jardine, et al.Diabetes, Obesity & Metabolism|July 22, 2020
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS ProgramDavid R Matthews, Carol Wysham, Melanie Davies, et al.Plos One|August 11, 2016
Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-AnalysisThaminda Liyanage, Toshiharu Ninomiya, Amanda Wang, et al.Diabetes, Obesity & Metabolism|November 16, 2019
Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS ProgramToshiaki Ohkuma, Luc Van Gaal, Wayne Shaw, et al.American Journal of Public Health|May 31, 2008
Socioeconomic disadvantage and kidney disease in the United States, Australia, and ThailandSarah L White, Kevin McGeechan, Michael Jones, et al.Journal of the American Geriatrics Society|March 19, 2025
The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE TrialsTu N Nguyen, Jie Yu, Vlado Perkovic, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 10, 2019
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trialVlado Perkovic, Audrey Koitka-Weber, Mark E Cooper, et al.The Cochrane Database of Systematic Reviews|February 27, 2017
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipientsClement Lo, Min Jun, Sunil V Badve, et al.Clinical Journal of the American Society of Nephrology : CJASN|September 30, 2020
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational TrialAdeera Levin, Vlado Perkovic, David C Wheeler, et al.Pageof 38